Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)-Reference-Cited by-同舟云学术

Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)

Published:2023-12-13 Issue:2 Volume:119 Page:130-145
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Usuki Kensuke^ORCID,Ohtake Shigeki,Honda Sumihisa,Matsuda Mitsuhiro,Wakita Atsushi,Nawa Yuichiro,Takase Ken,Maeda Akio,Sezaki Nobuo,Yokoyama Hisayuki,Takada Satoru,Hirano Daiki,Tomikawa Tatsuki,Sumi Masahiko,Yano Shingo,Handa Hiroshi,Ota Shuichi,Fujita Hiroyuki,Fujimaki Katsumichi,Mugitani Atsuko,Kojima Kensuke,Kajiguchi Tomohiro,Fujimoto Ko,Asou Norio,Usui Noriko,Ishikawa Yuichi,Katsumi Akira,Matsumura Itaru,Miyazaki Yasushi,Kiyoi Hitoshi

Funder

Japan Agency for Medical Research and Development

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

https://link.springer.com/content/pdf/10.1007/s12185-023-03686-9.pdf

Reference47 articles.

1. Maynadié M, et al. Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study. Haematologica. 2013;98(2):230–8.

2. Allemani C, et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385(9972):977–1010.

3. Chihara D, et al. Incidence of myelodysplastic syndrome in Japan. J Epidemiol. 2014;24(6):469–73.

4. Maynadié M, et al. Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population. Br J Cancer. 1996;74(2):288–90.

5. Germing U, et al. No increase in age-specific incidence of myelodysplastic syndromes. Haematologica. 2004;89(8):905–10.